STOCK TITAN

Catheter Precision (VTAK) Stock News

VTAK NYSE

Welcome to our dedicated page for Catheter Precision news (Ticker: VTAK), a resource for investors and traders seeking the latest updates and insights on Catheter Precision stock.

Catheter Precision, Inc. reports developments across cardiac electrophysiology medical devices and regional air mobility. The company’s medical technology updates center on VIVO, a non-invasive 3D imaging system for identifying ventricular arrhythmia origins before electrophysiology procedures, and LockeT, a suture retention device for wound closure after percutaneous venous punctures.

Recurring VTAK news also covers FDA and CE Mark status, clinical publications, medical conference activity, patent protection, product commercialization, and Flyte, its regional air mobility subsidiary. Flyte operates Cirrus Vision Jets for short-haul markets through an FAA-certified Part 135 air carrier platform.

Rhea-AI Summary

Catheter Precision, Inc. (VTAK) has received a purchase order for LockeT, its newest product, from the University of California San Diego (UCSD) health system. This order allows for product evaluations at the hospital to begin. CEO David Jenkins emphasized the importance of hospitals evaluating products before committing to long-term purchases. VP Robert Locke praised UCSD as an early adopter of new technologies in electrophysiology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
none
-
Rhea-AI Summary

Catheter Precision, Inc. (NYSE American: VTAK) released its Q1 2024 financials and operational report, highlighting key achievements and financial results. The company showcased progress in product development, clinical studies, and market expansion activities, along with a focus on talent acquisition to support future growth. With a solid financial position and a clear strategy, Catheter Precision aims to drive innovation in the field of cardiac electrophysiology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
-
Rhea-AI Summary

Catheter Precision, Inc. (NYSE-American: VTAK) announces Marie-Claude Jacques as the new Chief Commercial Officer. With a background in successful sales leadership at Baylis Medical and Boston Scientific, Jacques aims to drive growth and success for Catheter Precision.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.23%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.18%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.25%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.53%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.02%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.69%
Tags
none

FAQ

What is the current stock price of Catheter Precision (VTAK)?

The current stock price of Catheter Precision (VTAK) is $1.19 as of June 24, 2026.

What is the market cap of Catheter Precision (VTAK)?

The market cap of Catheter Precision (VTAK) is approximately 2.5M.